Anti-angiogenesis target therapy for advanced osteosarcoma
Osteosarcomas (OS), especially those with metastatic or unresectable disease, have limited
treatment options. The greatest advancement in treatments occurred in the 1980s when …
treatment options. The greatest advancement in treatments occurred in the 1980s when …
Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself
QK Yang, T Chen, SQ Wang, XJ Zhang, ZX Yao - Angiogenesis, 2020 - Springer
Bone and soft tissue sarcomas are rare malignant tumors originated from mesenchymal
tissues. They harbor more than 50 distinct subtypes and differ in pathological features and …
tissues. They harbor more than 50 distinct subtypes and differ in pathological features and …
First-line and sequential use of pazopanib followed by mammalian target of rapamycin inhibitor therapy among patients with advanced renal cell carcinoma in a US …
NJ Vogelzang, MD Hackshaw, TE Hutson… - Clinical genitourinary …, 2015 - Elsevier
Background Clinical trials have demonstrated that pazopanib prolongs progression-free
survival (PFS), with an acceptable safety profile, for patients with advanced renal cell …
survival (PFS), with an acceptable safety profile, for patients with advanced renal cell …
[HTML][HTML] Predictive factors for second-line therapy in metastatic renal cell carcinoma: a retrospective analysis
H Eggers, P Ivanyi, M Hornig… - Journal of Kidney Cancer …, 2017 - ncbi.nlm.nih.gov
Currently, about 50% of patients with metastatic renal cell carcinoma (mRCC) receive a
second-line therapy. Therefore, the choice at each subsequent treatment line remains an …
second-line therapy. Therefore, the choice at each subsequent treatment line remains an …
Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies
S Bracarda, D Castellano, G Procopio… - Expert opinion on …, 2014 - Taylor & Francis
Introduction: Axitinib, a highly selective inhibitor of vascular endothelial growth factor
receptors taken orally, is approved for second-line treatment of advanced renal cell …
receptors taken orally, is approved for second-line treatment of advanced renal cell …
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity
J Bellmunt, F Pons, A Foreshew, AP Fay… - Clinical Genitourinary …, 2014 - Elsevier
Abstract Introduction/Background Patients with metastatic renal cell carcinoma (mRCC) in
whom first-line therapies have failed might derive clinical benefit with sequential targeted …
whom first-line therapies have failed might derive clinical benefit with sequential targeted …
Sequential tyrosine kinase inhibitors (TKIs) in metastatic renal cell carcinoma: Results from a large cohort of patients
Background: Only scanty data are available to evaluate the impact of sequential TKIs on
overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). This …
overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). This …
Langzeitergebnisse der Erhaltungstherapie mit Gemcitabin nach Cisplatin-basierter adjuvanter Chemotherapie des operativ behandelten muskelinfiltrierenden …
A Svistunov - 2017 - opus.bibliothek.uni-wuerzburg.de
Der Stellenwert der Erhaltungstherapie mit Gemcitabin (GEM), die im Anschluss an die
Cisplatin-basierte Polychemotherapie (CBPC) bei den radikal operativ vorbehandelten …
Cisplatin-basierte Polychemotherapie (CBPC) bei den radikal operativ vorbehandelten …